Coronary Artery Calcium Score Australia: CV Risk Guide

Coronary artery calcium (CAC) scoring is one of the most informative investigations available for cardiovascular risk stratification in asymptomatic adults, and one of the most underutilised in routine Australian preventive care. A single low-radiation cardiac CT scan can identify subclinical atherosclerosis years or even decades before symptoms appear, reclassify risk in ways that change clinical decisions, and either prompt intervention or provide genuine reassurance depending on the result.

Understanding what the CAC score measures, how to interpret the Agatston number, what it costs in Australia, and how it integrates with lipid markers like ApoB and Lp(a) is increasingly relevant for anyone taking a proactive approach to cardiovascular health.

What Is a Coronary Artery Calcium Score?

The coronary artery calcium score is a non-contrast, low-radiation CT scan of the chest that detects and quantifies calcified plaques within the coronary arteries. Calcium deposits in coronary arteries are a marker of established atherosclerosis, they do not appear in healthy arterial walls. Their presence indicates that the atherosclerotic process has been underway long enough for calcification to occur.

The scan itself takes less than ten minutes. There is no intravenous contrast, no breath-hold beyond a few seconds, and radiation exposure is roughly equivalent to a mammogram or a few months of background environmental radiation.

How the Agatston Score Is Calculated

The standard output of a CAC scan is the Agatston score, named after cardiologist Arthur Agatston who developed the scoring method in 1990. The Agatston score is calculated by multiplying the area of each calcified lesion (in mm²) by a density weighting factor based on Hounsfield units:

• Density 130–199 HU → weight factor 1
• Density 200–299 HU → weight factor 2
• Density 300–399 HU → weight factor 3
• Density ≥400 HU → weight factor 4

Scores across all coronary segments are summed to produce the total Agatston score. Modern cardiac CT platforms calculate this automatically. Some centres also report CAC volume (mm³) and CAC mass, though the Agatston score remains the most widely validated metric for risk prediction.

Interpreting the Agatston Score

Standard Score Categories

These categories reflect population-level risk thresholds, but the clinical picture is never purely about the number. A score of 50 in a 45-year-old is more concerning than the same score in a 72-year-old, because it indicates earlier-than-expected plaque accumulation relative to age.

Percentile-Based Interpretation

Raw Agatston scores are best interpreted against age- and sex-matched percentiles, because calcium accumulation is strongly age-dependent. Reference databases, including those derived from the MESA (Multi-Ethnic Study of Atherosclerosis) cohort, allow clinicians to classify a patient's score as below the 25th percentile (low for age), median, or above the 75th or 90th percentile (high for age).

A 55-year-old man with an Agatston score of 100 might be at the 50th percentile for his demographic, unremarkable relative to peers. The same score in a 38-year-old man would place him in the top few percent, signalling significantly premature vascular ageing.

MESA percentile calculators are publicly available and take age, sex, race, and smoking status as inputs. Australian cardiologists increasingly use these tools alongside the raw score.

The Power of Zero

A CAC score of 0 is clinically meaningful in its own right. Large prospective studies, including MESA and the Coronary Artery Calcium Consortium, have demonstrated that a score of 0 in low-to-intermediate risk adults confers a very low 10-year risk of major adverse cardiovascular events, comparable to or lower than individuals in the lowest Framingham risk category.

This "power of zero" has real clinical utility: it can justify deferring statin therapy in intermediate-risk individuals who might otherwise warrant treatment, and it provides genuine reassurance to anxious patients with borderline lipid values but no detectable plaque. Importantly, a CAC of 0 does not mean zero lifetime risk, it means near-term risk is low, and the result typically warrants re-scanning in five to seven years.

Evidence Base: What MESA and Other Large Cohorts Show

The strongest evidence for CAC scoring comes from the Multi-Ethnic Study of Atherosclerosis (MESA), a prospective cohort of over 6,800 participants aged 45 to 84 followed from 2000 onwards. MESA established that the CAC score adds independent prognostic information beyond traditional Framingham risk factors, reclassifies a substantial proportion of intermediate-risk individuals into higher or lower risk categories, and predicts cardiovascular events with better discrimination than risk scores based on age, cholesterol, blood pressure, and smoking alone.

These findings directly shaped the 2013 ACC/AHA cholesterol guidelines, particularly the recommendation to consider CAC scoring in patients where treatment decisions remain uncertain after standard risk assessment. A detailed review of MESA's contributions to cardiovascular risk evidence is available via PMC.

CAC Progression and Prognosis

A single CAC measurement is informative, but serial measurements add another layer of prognostic value. Research published in JACC: Cardiovascular Imaging demonstrated that progression of coronary artery calcium, defined as a >15% annual increase in Agatston score, is independently associated with higher all-cause mortality. This progression study is indexed on PubMed.

In practical terms: a patient with a CAC of 80 who rescans three years later and finds a score of 180 has demonstrated rapid progression, a more concerning signal than a static score of 180 in someone scanned for the first time at the same age. Progression data also allows assessment of whether treatment is adequately stabilising the plaque burden.

Optimal Targets by Age

There are no universally agreed "optimal" Agatston targets the way there are for cholesterol or blood pressure. The clinical goal is:

• Under 50: A score of 0 is genuinely reassuring. Any detectable calcium warrants investigation of contributing risk factors.
• 50–60: A score below the 50th percentile for age, sex, and ethnicity is acceptable. Above the 75th percentile should prompt aggressive risk factor management.
• 60–70: Some calcium accumulation is common. Absolute scores above 300–400 are high risk. Percentile positioning remains the most useful frame.
• Over 70: Very high scores (≥1000) in older adults confer extremely elevated risk, but treatment decisions weigh comorbidities and life expectancy.

The goal of serial monitoring is stability or slow progression, not necessarily reaching a score of 0 once calcium is present.

When to Get a CAC Score in Australia

CAC scoring is most useful in intermediate-risk asymptomatic adults where the decision to initiate or withhold preventive therapy is genuinely uncertain. It adds less value at the extremes: very low-risk individuals are unlikely to have detectable calcium, while very high-risk individuals (known CVD, diabetes with end-organ damage, severely elevated Lp(a)) already have clear treatment indications.

Scenarios where a CAC score is particularly worth considering:

• Statin decision uncertainty: ApoB or LDL-C in the borderline range; patient reluctant to start long-term medication
• Premature family history: Parent or sibling with coronary artery disease before age 55–60
• Elevated Lp(a): Lp(a) above 50 mg/dL (125 nmol/L) without other clear risk markers; CAC helps determine whether genetic risk has translated into actual plaque
• Metabolic syndrome: Insulin resistance, elevated triglycerides, low HDL, standard lipid panels may underestimate particle burden, just as they overlook omega-3 fatty-acid status as a modifiable risk factor
• South Asian ethnicity: Significantly higher CAC prevalence at equivalent ages compared to European-ancestry populations; earlier screening is often warranted

CAC is not appropriate as a first-line investigation for acute chest pain, symptomatic patients, or those already established on intensive lipid-lowering therapy where the result is unlikely to change management.

Australian Context: Costs and Access

Medicare and MBS Coverage

Coronary artery calcium scoring is not covered by Medicare in Australia as a standalone preventive item. It is not listed on the MBS as an independently rebatable service, making it an out-of-pocket expense for most Australians seeking it for primary prevention purposes.

The related but distinct test, CT coronary angiography (CTCA), is available under MBS items 57360 and 57364 for patients meeting specific eligibility criteria (symptomatic patients with low-to-intermediate pre-test probability of obstructive coronary artery disease). A CAC score obtained as part of a CTCA procedure is not charged separately, but the indication criteria are narrower and require a clinical referral pathway.

The Heart Foundation of Australia acknowledges the evidence for CAC scoring in primary prevention guidelines, but as of 2026 there is no movement toward full Medicare rebating for preventive CAC scanning in asymptomatic adults.

Private Cost

Private CAC scans are available at radiology centres across Australia, typically ordered by a GP or cardiologist. Costs vary by provider and state:

• Sydney, Melbourne, Brisbane: Typically $150–$250
• Regional centres: May be higher due to limited availability; some patients travel to metropolitan centres
• Bundled preventive assessments: Some private cardiology practices include CAC as part of a broader cardiovascular screening package

Most private health insurance extras policies do not cover CAC scanning, as it is classified as diagnostic imaging rather than general extras. A minority of comprehensive ancillary policies may apply partial rebates, worth checking with your insurer before booking.

For a test with this level of prognostic utility, many Australians find a $150–$250 CAC scan to be among the higher-value preventive investigations available outside the public system.

Integrating CAC With Lipid Markers

ApoB and CAC

ApoB counts the number of atherogenic lipoprotein particles, LDL, VLDL, IDL, and Lp(a). It reflects the ongoing exposure of coronary arteries to particle-driven atherosclerosis. CAC measures the cumulative structural result of that exposure.

The two markers are complementary rather than redundant. Elevated ApoB without detectable CAC may indicate early risk not yet manifested as plaque, particularly relevant in younger adults. Detectable CAC despite relatively normal ApoB suggests either past exposure now better controlled, genetic susceptibility, or unmeasured contributors. The combination of elevated ApoB and high CAC-for-age is a strong signal for intensive treatment.

Lp(a) and CAC

Lp(a) preferentially accumulates in calcified coronary plaque, and large Mendelian randomisation studies confirm its causal role in coronary artery disease and aortic stenosis. Patients with Lp(a) above 100 mg/dL (250 nmol/L) who also have a high CAC score, particularly above the 75th percentile for age, represent a group with compounded genetic and structural risk.

Because Lp(a) cannot be meaningfully lowered with current standard therapies, the CAC result in these patients primarily informs the urgency of managing other modifiable risk factors: intensive ApoB reduction, blood pressure optimisation, inflammation control, and lifestyle modification.

hsCRP and CAC

High-sensitivity CRP, covered in detail in the hsCRP and inflammation guide, reflects inflammatory activity in arterial walls and systemic tissues. Some patients have elevated hsCRP with low CAC, suggesting active inflammation without yet-calcified plaque. Others have high CAC with normal hsCRP, indicating established hard plaque with relatively quiescent inflammatory signalling.

Together, CAC and hsCRP build a more nuanced picture of both the structural (how much plaque is present) and biological (how active is that plaque) dimensions of cardiovascular risk.

Standard Lipid Panel and CAC

A comprehensive lipid panel (total cholesterol, LDL-C, HDL-C, and triglycerides) remains the starting point for most cardiovascular risk assessments. CAC scanning is most useful when the lipid panel leaves genuine uncertainty: borderline LDL-C, discordant HDL, or metabolic dyslipidaemia patterns where particle number diverges from cholesterol concentration.

Practical Considerations for Patients

How to access a CAC scan in Australia: Most radiology providers require a referral from a GP, cardiologist, or other specialist. A standard GP referral is sufficient at most centres. Discuss your risk factors, family history, and any treatment decision uncertainty with your GP.

What to expect: The scan takes 10–15 minutes total including positioning. It is performed without contrast, requires a brief breath-hold, and is non-invasive. Results are typically available within 1–3 business days as a radiologist report with the numerical Agatston score and a brief clinical interpretation.

Repeat scanning: For patients with a score of 0, a repeat scan in 5–7 years is reasonable depending on risk factor trajectory. For patients with detectable calcium, repeat intervals depend on baseline score and treatment response, typically 3–5 years for moderate scores, potentially longer once stability is established.

Radiation consideration: Modern CAC protocols use prospective ECG gating to minimise radiation dose. Effective dose is typically 0.5–1.5 mSv, comparable to a few months of background environmental radiation. It is not a meaningful concern for a test performed once every 3–7 years in adults.

Key Takeaways

• The coronary artery calcium score quantifies calcified coronary plaque via a low-radiation cardiac CT scan; the Agatston score is the standard output
• A score of 0 confers very low near-term cardiovascular event risk and can safely support deferral of statin therapy in intermediate-risk adults
• Scores above the 75th percentile for age and sex signal premature atherosclerosis and typically warrant intensified risk factor management
• CAC progression of >15% per year is independently associated with higher all-cause mortality
• In Australia, CAC scoring is not Medicare-rebatable as a standalone preventive scan; private cost is typically $150–$250
• CAC integrates most powerfully with ApoB, Lp(a), and hsCRP to build a complete picture of cardiovascular risk burden
• Intermediate-risk adults facing statin decisions, those with elevated Lp(a), or those with premature family history are the highest-value candidates for CAC scanning in Australia